Some studies have demonstrated that the use of everolimus, a selective mTOR inhibitor, in combination with ribociclib (a kinase inhibitor) or bortezomib (a proteosome inhibitor), can enhance inhibition of tumor growth and lead to stable disease, increasing overall survival [47,48]. The gene discussed is MTOR; the disease is neoplasm.